About this episode
The genetic testing company 23andMe filed for bankruptcy in March, after years of slowing sales, legal trouble, and a declining stock price. And now, the valuable trove of genetic data the company owns is for sale, sparking privacy concerns.
On today’s Big Take, Bloomberg biotech reporter Gerry Smith traces the rise and fall of 23andMe, and bankruptcy reporter Jonathan Randles outlines what a possible sale could mean for millions of users’ genetic data.
Read more: Bankrupt 23andMe’s DNA Data Gets Sale Nod as Concerns Linger
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time Big Take publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Big Take
So Could AI 'Kill Us All'?
Big Take
Trump Needs a Win. Enter His Venezuela Oil Deal
Big Take
Why the Bond Market Has Everyone On Edge
Big Take
Americans Are Spending Billions to Help Their Pets Live Longer
Big Take